CVRx, Inc.CVRXEarnings & Financial Report
Nasdaq · Health Care · Surgical & Medical Instruments & Apparatus
CVRx, Inc. is a commercial-stage medical technology company specializing in neuromodulation therapies for chronic cardiovascular diseases. Its flagship Barostim system treats heart failure and resistant hypertension, with core markets across North America and Europe, serving patients unresponsive to conventional drug treatments.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| S.S. OR | 17.00% | 4.1M | ▼ -2.20pp | 2024-11-01 |
| New Enterprise Associates 8A, Limited Partnership | 9.30% | 2.2M | — | 2024-11-07 |
| Vensana Capital I GP, LLC | 8.20% | 1.7M | — | 2024-02-06 |
| Cooperatieve Gilde Healthcare IV U.A. | 7.70% | 1.6M | — | 2023-12-29 |
| Cooperatieve | 6.60% | 1.4M | — | 2024-01-19 |
Insider Transactions
Net 90d: +$173.8K · buys $300.4K / sells $126.6KRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-03-02 | Adamson Philip B. | Chief Medical Officer | Sell (open market) | 1.3K | $7.90 | $10.0K |
| 2026-03-02 | Gregory Morrison | CHIEF HUMAN RESOURCES OFFICER | Grant | 34.0K | $0.00 | $0 |
| 2026-03-02 | VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER | Sell (open market) | 1.3K | $7.90 | $10.1K |
| 2026-03-02 | Kevin Hykes | PRES & CEO | Sell (open market) | 7.8K | $7.90 | $61.3K |
| 2026-03-02 | OASHEIM JARED | CHIEF FINANCIAL OFFICER | Sell (open market) | 1.7K | $7.90 | $13.8K |
| 2026-03-02 | John Robert Allen | Chief Revenue Officer | Sell (open market) | 4.0K | $7.90 | $31.3K |
| 2026-02-27 | Adamson Philip B. | Chief Medical Officer | Grant | 41.0K | $0.00 | $0 |
| 2026-02-27 | VERRASTRO PAUL | CHIEF MKTG & STRAT OFFICER | Grant | 45.0K | $0.00 | $0 |
| 2026-02-27 | Kevin Hykes | PRES & CEO | Grant | 159.0K | $0.00 | $0 |
| 2026-02-27 | OASHEIM JARED | CHIEF FINANCIAL OFFICER | Grant | 61.0K | $0.00 | $0 |
1–10 of 14
Page 1 / 2